Development of a novel program to facilitate monitoring physical health and adverse effects in children and adolescents prescribed antipsychotic medication

Australasian Psychiatry

Volumn 16, Issue 5, 2008, Pages 368-369

  Ellis, David ^a   Shirzadi, Kambiz ^a   Grzeskowiak, Luke ^a   Angley, Manya ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ACCESS TO INFORMATION; AUSTRALIA; CHILD PSYCHIATRY; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DIABETES MELLITUS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE DELIVERY; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERPROLACTINEMIA; LETTER; LIVER DISEASE; LONG TERM CARE; PEDIATRICIAN; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIST; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DRUG PRESCRIPTIONS; HEALTH PROMOTION; HEALTH STATUS; HUMANS; MENTAL DISORDERS; PHYSICAL FITNESS; PROGRAM DEVELOPMENT;

EID: 51849102829     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1080/10398560802010407     Document Type: Letter

References (14)

1. Walter, G., DeLaroche, A. Soh, N. et al. (2008) Side effects of second generation antipsychotics: The experience, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry
2. Australian Medicines Handbook (2008) Australian Medicines Handbook, Adelaide
3. American Academy of Child and Adolescent Psychiatry (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child & Adolescent Psychiatry, 40, pp. S4-S23.
4. Lewis, R. (1998) Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry, 43, pp. 596-604.
5. Sikich, L., Hamer, RM, Bashford, RA, Sheitman, BB and Lieberman, JA. (2004) A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29, pp. 133-145.
6. Martin, A., Scahill, L. Anderson, GM et al. (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. American Journal of Psychiatry, 161, pp. 1125-1127.
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry, 65, pp. 267-272.
8. Marder, SR, Essock, SM Miller, AL et al. (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, pp. 1334-1349.
9. Lambert, TJR and Chapman, LH. (2004) Diabetes, psychotic disorders and antipsychotic therapy; a consensus statement. Medical Journal of Australia, 181, pp. 544-548.
10. Remington, G. (2006) Schizophrenia, antipsychotics, and the metabolic syndrome: Is there a silver lining?. American Journal of Psychiatry, 163, pp. 1132-1134.
11. Department of Health and Ageing (2002) The National Strategy for Quality Use of Medicines, Commonwealth of Australia, Department of Health and Ageing, Canberra
12. Grimshaw, J., Thomas, R. MacLennan, G. et al. (2004) Effectiveness and efficiency of guidelines dissemination and implementation strategies. Health Technology Assessment, 8, pp. 1-72.
13. Grimshaw, J., Shirran, L. Thomas, R. et al. (2001) Changing provider behaviour: An overview of systematic reviews of interventions. Medical Care, 39, pp. 2-45.
14. Grzeskowiak, LE, Ellis, DP, Phillips, AJ and Angley, MT. (2008) Journal of Pharmacy Practice and Research